Medication Overview

Rinvoq (upadacitinib)    is an oral medication used to treat various inflammatory conditions, including moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by blocking specific pathways that cause inflammation.

Who Should Consider Rinvoq?     Rinvoq is suitable for adults who:

  • Have moderate to severe rheumatoid arthritis and have not responded well to one or more disease-modifying antirheumatic drugs (DMARDs).
  • Suffer from psoriatic arthritis or ankylosing spondylitis and require an alternative to or have not responded to standard therapies.
  • Are diagnosed with moderate to severe ulcerative colitis and have not adequately responded to other treatments.

How is Rinvoq Administered? Rinvoq is taken orally, usually once a day. The pill should be swallowed whole with water, with or without food.

Important Information for Rinvoq Users:

  • How to Use: Follow your healthcare provider’s dosage instructions carefully.
  • Storage: Store Rinvoq at room temperature, away from moisture and heat.
  • Side Effects: Common side effects include upper respiratory tract infections, nausea, and elevated liver enzymes. Serious side effects can include blood clots, severe infections, and cancer. Report any severe or unexpected symptoms to your healthcare provider.
  • Monitoring: Regular medical check-ups and possibly blood tests are recommended to monitor your health and the medication’s effectiveness, especially liver function and blood cell counts.

Medication Warnings

  • Infections: Rinvoq can compromise the immune system, increasing the risk of serious infections. Promptly report any signs of infection, such as fever, chills, or persistent cough, to your healthcare provider.
  • Blood Clots: There is an increased risk of blood clots, which can be serious and lead to death. Watch for symptoms of thrombosis such as swelling, pain, or redness in the limbs.
  • Cancer: JAK inhibitors, including Rinvoq, may increase the risk of certain cancers. Discuss your cancer risk with your doctor.
  • Liver Problems: Rinvoq can cause liver problems. Regular monitoring of liver function is recommended.
  • Cholesterol Levels: Treatment with Rinvoq may affect your cholesterol levels. Blood tests to monitor these levels should be conducted regularly.

Who Should and Shouldn’t Take Rinvoq?

  • Suitable Candidates:
    • Adults with specific inflammatory conditions who require a JAK inhibitor for treatment.
  • Unsuitable Candidates:
    • Individuals with active, severe infections.
    • Patients with known hypersensitivity to upadacitinib or any components of the formulation.
    • Those at increased risk for blood clots or with a history of liver disease.

For more detailed information and personalized advice, consult your healthcare provider.